PharmaShots Weekly Snapshots (March 11 – March 15, 2024)

Share this

PharmaShots Weekly Snapshots (March 11 – March 15, 2024)

This week PharmaShots’ news was all about the updates on Regulatory, Clinical Trials, M&As, Pharma, Digital Health, Animal Health & MedTech. Check out our full report below:

Johnson & Johnson Submits sBLA of Tremfya to the US FDA for the Treatment of Ulcerative Colitis

Read More: Johnson & Johnson                                                       

Travere Therapeutics Submits sNDA of Filspari (sparsentan) to the US FDA to Treat IgA Nephropathy (IgAN)

Read More: Travere Therapeutics                                                       

The US FDA Grants Orphan Drug Designation to Terns Pharmaceuticals’ TERN-701 for Treating Chronic Myeloid Leukemia

Read More: Terns Pharmaceuticals                                                       

InnoCare Reports Approval to Initiate Clinical Study of ICP-248 in Combination with Orelabrutinib for Treating CLL/SLL in China

Read More: InnoCare                                                                

The EC Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine for the Protection Against Pneumococcal Disease in Pediatric Population

Read More: Pfizer                                                                         

Daiichi Sankyo Reports NDA Submission of Datopotamab Deruxtecan to the MHLW for Treating Advanced Breast Cancer

Read More: Daiichi Sankyo                                                              

The US FDA Grants Accelerated Approval to BMS’ Breyanzi for Treating R/R Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Read More: BMS                                                                      

BeiGene’s Tevimbra Gains the US FDA’s Approval for Treating Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Read More: BeiGene                                                                     

Eli Lilly Highlights the P-III Trial Results of Lebrikizumab for People with Skin of Color and Moderate-to-Severe Atopic Dermatitis at American Academy of Dermatology (AAD) Annual Meeting

Read More: Eli Lilly                                                                   

Incyte Features the P-II Study Data of Povorcitinib to Treat Prurigo Nodularis at AAD’24

Read More: Incyte                                                                     

Sanofi Highlights Results from the P-IIb (STREAM-AD) Trial of Amlitelimab for Treating Atopic Dermatitis at AAD’24

Read More: Sanofi                                                                  

Sensorion Reports the P-IIa Study Results of SENS-401 for Residual Hearing Preservation 

Read More: Sensorion                                                                

Acadia Pharmaceuticals Highlights Results from the P-III (ADVANCE-2) Trial of Pimavanserin for Treating Negative Schizophrenia Symptoms

Read More: Acadia Pharmaceuticals                                        

Larimar Therapeutics Reports First Patient Dosing with Nomlabofusp in the Open Label Extension Trial for the Treatment of Friedreich’s Ataxia

Read More: Larimar Therapeutics                                           

Pfizer Reports Data from the P-III (ECHELON-3) Clinical Evaluation of Adcetris for the Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Read More: Pfizer                                                                          

Astrocyte Pharmaceuticals’ Receives the US FDA’s IND Clearance of AST-004 for the Treatment of Acute Ischemic Stroke

Read More: Astrocyte Pharmaceuticals                                       

89bio Reports Commencement of the P-III (ENLIGHTEN) Study Evaluating Pegozafermin for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Read More: 89bio                                                                  

Longbio Pharma Presents the P-I Trial Results of LP-003 for the Treatment of Chronic Spontaneous Urticaria at AAD 2024

Read More: Longbio Pharma                                                          

Merck Highlights the P-III (KEYNOTE-A18) Study Results of Keytruda for Treating Cervical Cancer

Read More: Merck                                                                        

Boehringer Ingelheim and Sosei Heptares Partner for the Development of Therapies Addressing Schizophrenia Symptoms

Read More: Boehringer Ingelheim & Sosei Heptares                   

Merck and Pearl Bio Partner for the Discovery of Novel Biological Therapies to Treat Cancer

Read More: Merck & Pearl Bio                                                     

Bayer Join Forces with Aignostics to Strengthen its Precision Oncology Portfolio

Read More: Bayer & Aignostics                                                    

Biotheus and Hansoh Pharma Expand their Collaboration to Develop EGFR/cMET Bispecific Antibody-Drug Conjugates

Read More: Biotheus & Hansoh Pharma                                            

Celltrion Submits BLA to the US FDA for its Biosimilar Version of Xolair, CT-P39 

Read More: Celltrion                                                                  

Roche Reports Introduction of navify Digital Solutions for its Use in Laboratories and Point of Care Services at HIMSS 2024

Read More: Roche                                                                  

Novartis to Acquire IFM Due (Subsidiary of IFM Therapeutics) for the Development of STING Antagonist Program

Read More: Novartis & IFM Therapeutics                                       

For an Aggregate of ~$1.05B, AstraZeneca to Acquire Amolyt Pharma

Read More: AstraZeneca & Amolyt Pharma                                       

The US FDA Grants Breakthrough Device Designation to SetPoint Medical’s Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis

Read More: SetPoint Medical                                                

HeartBeam Reports Patient Enrollment in the Trial Investigating AIMIGo System for Arrhythmia Detection

Read More: HeartBeam                                                       

Cresilon Introduces Animal Philanthropy Program, VETIGEL Gives, to Provide Surgeries for Animals in Need

Read More: Cresilon                                                              

Related Post: PharmaShots Weekly Snapshots (March 04 – March 08, 2024)

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions